VolitionRx Limited
VNRX•NYSEAMERICAN•Healthcare•Medical Devices

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is based in Henderson, Nevada.

Company Information

SectorHealthcare
IndustryMedical Devices
CEOCameron Reynolds
Employees85
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNYSEAMERICAN (NYSEAMERICAN)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitevolition.com
Phone646 650 1351
Address
1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 United States

Corporate Identifiers

CIK0000093314
CUSIP928661107
ISINUS9286611077
EIN91-1949078
SIC2835

Leadership Team & Key Executives

Dr. Salvatore Thomas Butera DVM
Chief Executive Officer of Volition Veterinary Diagnostics Development LLC
Cameron Reynolds MBA
Founder, Chief Executive Officer, President and Director
Dr. Gaetan Michel Ph.D.
Chief Operating Officer
Terig Hughes
Chief Financial Officer and Treasurer
Dr. Jacob Vincent Micallef MBA, Ph.D.
Chief Scientific Officer
Nicholas Plummer
Group General Counsel
Louise Batchelor Day
Group Chief Marketing and Communications Officer
Gael Forterre M.B.A.
Chief Commercial Officer
Sharon Ballesteros
U.S. Head of Quality and Development Process
Dr. Andrew Retter MBBS
Chief Medical Officer